London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.
Microfracture creates fibrocartilage deficient in glycosaminoglycans, the molecules that absorb joint compression; this tissue progressively fails from year two. ChondroFiller injection uses a collagen scaffold to avoid bone damage and sustain organised repair through years two to five.
Most meniscus tears, particularly degenerative ones in adults over 35, respond to physiotherapy as well as surgery. Randomised trials show conservative management preserves the surgical option if needed, with equivalent long-term outcomes.
Each pound of weight lost removes four pounds of mechanical force per step; a sustained 5–10% weight reduction produces clinically significant improvements in pain and function.
ChondroFiller injection places a collagen scaffold that solidifies in the joint and prompts acellular matrix-induced chondrogenesis: progenitor cells colonise the scaffold and lay down new tissue over six to twenty-four months, with IKDC functional scores improving by roughly thirty points over three years.
ChondroFiller, an injectable collagen scaffold, recruits progenitor cells to rebuild cartilage in focal defects; widespread thinning and synovial inflammation cannot be addressed by the scaffold alone and require combined treatment.
Cartilage defects follow a distinctive trajectory: months or years with no obvious symptoms, then fairly abrupt deterioration. This occurs because cartilage lacks the blood supply needed to repair itself.
